EXAS VS SZLS 2019 Without CovidEXAS: MADISON, Wis., Feb. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $295.6 million for the fourth quarter ended Dec. 31, 2019 and $876.3 million for the full year ended Dec. 31, 2019, including Precision Oncology revenue of $66.2 million for the period Nov. 8, 2019 through Dec. 31, 2019, following the close of the Genomic Health combination.
SZLS: 2019 Financial Results All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.
For the year ended December 31, 2019, we reported revenue of $0.1 million and a consolidated net loss of $3.5 million, or $0.02 loss per common share.
